SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Germany
· Delayed Price · Currency is EUR | Market Cap | 2.11B |
| Revenue (ttm) | 995.03M |
| Net Income (ttm) | 149.95M |
| Shares Out | 150.61M |
| EPS (ttm) | 0.99 |
| PE Ratio | 14.13 |
| Forward PE | 14.39 |
| Dividend | 0.18 (1.29%) |
| Ex-Dividend Date | Feb 4, 2026 |
| Volume | 89,836 |
| Average Volume | 115,391 |
| Open | 14.24 |
| Previous Close | 14.20 |
| Day's Range | 13.86 - 14.38 |
| 52-Week Range | 13.76 - 30.25 |
| Beta | 0.92 |
| RSI | 38.59 |
| Earnings Date | Feb 11, 2026 |
About ETR:1SXP
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold application... [Read more]
Financial Performance
In fiscal year 2025, ETR:1SXP's revenue was 986.21 million, an increase of 3.04% compared to the previous year's 957.09 million. Earnings were 146.45 million, a decrease of -2.16%.
Financial StatementsNews
EQS-DD: SCHOTT Pharma AG & Co. KGaA: Dr. Torsten Derr, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 12.02.2026 / 11:32 CET/CEST The issuer is solely responsi...